• Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Oryzon Genomics S.A.

Headquarters: Barcelona, Spain
Website: https://www.oryzon.com/en
Year Founded: 2000
Status: Public
Industry Sector: HealthTechnology
CEO: Carlos Manuel Buesa Arjol, PhD
Number Of Employees: 46
Enterprise Value: $102,705,550
PE Ratio: -45.85
Exchange/Ticker 1: Madrid:ORY
Exchange/Ticker 2: N/A
Latest Market Cap: $230,204,229

BioCentury | Jan 24, 2024
Data Byte

Schizophrenia pipeline: two PDUFA dates and a dozen readouts in 2024

A look ahead to the schizophrenia milestones coming this year, and the mechanisms behind them
Read More
BioCentury | Sep 12, 2023
Emerging Company Profile

Actio seeks rare toeholds into common diseases with $55M A round

Led by geneticist David Goldstein, the San Diego company thinks its ‘one-to-many’ strategy builds the economic case for going after very rare diseases
Read More
BioCentury | Jan 11, 2023
Management Tracks

Kevin Tan becomes CFO at Solid

Plus: Shook promoted to CMO at Nkarta, and updates from HilleVax, Neurotech, Akero, LifeSci, Dunad and more
Read More
BioCentury | Nov 21, 2022
Deals

High-premium Imago takeout gives Merck hematology asset nearing Phase III

Public since 2021, biotech led by former FerroKin team generates final exit at ten-figure price
Read More
BioCentury | Mar 28, 2022
Management Tracks

Asif Ali to join Protagonist as CFO

Plus new CMO at Avenge Bio, new CEO at 
Read More
BioCentury | Jan 15, 2022
Management Tracks

Founder El-Hibri to retire from Emergent

Plus CEO Sandanayaka shifts to CSO at Nirogy, and updates from Angelini, Apie, 
Read More
BioCentury | Dec 6, 2018
Translation in Brief

Opening chromatin: long-term detriment?

Enhancing chromatin accessibility in cancer could be a liability, not a benefit
Read More
BioCentury | Dec 8, 2017
Targets & Mechanisms

Epiphenomena at ASH

Epigenetics and cell therapies are preclinical hotspots at ASH 2017
Read More
BioCentury | Jul 21, 2017
Company News

Roche ends cancer deal with Oryzon

Read More
BioCentury | Jul 20, 2017
Company News

Roche ends cancer deal with Oryzon

Read More
Items per page:
1 - 10 of 28
Help Center
Username
Request Training
Submit Data Correction
Ask a Question
Elevio by Dixa